The RheumNow Week in Review – 28 July 2017 Save

Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com:

1. Biologics makes for ~90% of cost of RA care - infusions cost/Yr RTX $36,663; TCZ $36,821, INFLX $4,973; ABA $46,532 https://t.co/HJNaVh4A5m
2. EU/EMA follows FDA decision to approve Orencia (abatacept) for use in active psoriatic arthritis as mono or combo Rx https://t.co/RkxRsGKahQ
3. NIH/NIAID phase I & II trial of MV-CHIKV, a recombinant, live-attenuated measles vax expressing chikungunya proteins https://t.co/UjAQelwz8r
4. Retrospective study 1171 ANCA+ vasculitis shows 16% w/ inflamm ocular disease – Half with eye pain, 16% visuall loss: Scleritis 22% episcleritis 21%, Uveitis 9%  https://t.co/qqrXgaLkBf
5. RCT shows ustekinumab or guselkumab does NOT significantly reduce the signs and symptoms of RA. https://t.co/14N8ZsKbZ3
6. Discrepancy between ultrasound and DECT quantification of urate tophi in gout joints; lower sensitivity with DECT https://t.co/RL5Vkq6GSz
7. Samsung Bioepis launches U.S. sales of Remicade biosmiliar- Renflexis https://t.co/emo6Te0yyW
8. Biosimilar Pricing Wars Have Begun  
9. Baricitinib Derailed by FDA Review
10. Benlysta FDA Approved for Sub-Q Use in Lupus 
11. Increased Pulmonary Embolism Risk in Lupus Patients